Pharmacotherapy for schizophrenic inpatients in East Asia - Changes and challenges

International Review of Psychiatry

Volumn 20, Issue 5, 2008, Pages 460-468

  Shinfuku, Naotaka ^a   Tan, Chay Hoon ^b  

^a SEINAN GAKUIN UNIVERSITY   (Japan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; EMONAPRIDE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERICIAZINE; PEROSPIRONE; PERPHENAZINE; PIPOTIAZINE PALMITATE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL DECANOATE;

ASIA; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR SYMPTOM; CHINA; ENDOCRINE DISEASE; HEALTH SURVEY; HONG KONG; HUMAN; JAPAN; KOREA; METABOLIC DISORDER; MOTOR DYSFUNCTION; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; REVIEW; SCHIZOPHRENIA; SINGAPORE; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; FAR EAST; HUMANS; INPATIENTS; LIFE EXPECTANCY; PRESCRIPTION DRUGS; SCHIZOPHRENIA;

EID: 56549114654     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260802397560     Document Type: Review

References (28)

1. Chong, M. Y., Tan, C. H, Fujii, S., Yang, S. Y., Ungvari, G., & Si, T., et al. (2004). Antipsychotic drug prescription for Schizophrenia in East Asia: A rationale for change. Psychiatry and Clinical Neurosciences, 58(1), 61-67.
2. Davies, L. M., Lewis, S., Jones, P. B., Barnes, T. R., Gaughran, F., & Hayhurst, K., et al. (2007). Cost-effectiveness of first- v. second-generation antipsychotic drugs: Results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry, 191, 14-22.
3. Fujii, S., Maeda, K., & Shinfuku, N. (2003). Survey on psychotropic drug prescription pattern in six countries and areas in East Asia. Rinsyo Seizing Iguaçu, 32(6), 629-646 (In Japanese).
4. Fujii, S., & Shinfuku, N. (2004). The characteristics of pharmacotherapy for the inpatients with schizophrenia in Japan - Comparison with other countries and regions. Rinsyo Seisin Yakuri, 7(1), 3-14 (In Japanese).
5. Fujii, S., & Shinfuku, N. (2005). Utilization of levomepromazine in Japan - Its role as an antipsychotic in psychiatric pharmacotherapy. Rinsyo Seisin Yakuri, 8(8), 1227-1238 (In Japanese).
6. Hung, G. B., & Cheung, H. K. (2008). Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Medical Journal, 14(1), 35-39.
7. Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., & Hayhurst, K. P., et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63, 1079-1087.
8. Law, W. L., Hui, H. Y., Young, W. M., & You, J. H. (2007). Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - A cost analysis. International Journal of Clinical Pharmacopsychiatric Therapy, 45, 264-270.
9. Lee, C., Wu, K. H., Habil, H., Dyachkova, Y., & Lee, P. (2006). Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Australia and New Zealand Journal of Psychiatry, 40(5), 437-445.
10. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, Perkins, R. A., et al. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
11. Rothbard, A. B., Kuno, E., & Foley, K. (2003). Trend in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin, 29(3), 531-540.
12. Scheen, A. J., & De Hert, M. A. (2007). Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes and Metabolism, 33(3), 169-175.
13. Shiloh, R., Nutt., & Weizman, A. (2000). Atlas of psychiatric pharmacotherapy, Revised. London: Martin Dunitz.
14. Sim, K., Su, A., Leong, J. Y., Yip, K., Chong, M. Y., Fujii, S., et al. (2004a). High dose antipsychotic use in schizophrenia: Findings of the REAP (Research on East Asia Psychotropic Prescriptions) study. Pharmacopsychiatry, 37(4), 175-179.
15. Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., et al. (2004b). Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(2), 178-183 Erratum in: British Journal of Clinical Pharmacology, 58(5), 564.
16. Sim, K., Su, A., Ungvari, G. S., Fuji, i S., Yang, S. Y., Chong, M. Y., et al. (2004c). Depot antipsychotic use in schizophrenia: An East Asian perspective. Human Psychopharmacology, 19, 103-109.
17. Sim, K., Lee, N. B., Chua, H. C., Mahendran, R., Fujii, S., Yang, S. Y., et al. (2007). Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. British Journal of Clinical Pharmacology, 63, 431-437.
18. Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., et al. (2007). CATIE Investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. American Journal of Psychiatry, 2(164), 428-436.
19. Tandon, R., Belmaker, R. H., Wagner, F., Gattaz, J., Lopez-Ibor Jr., Okasha, A., et al., & the Section of Pharmacopsychiatry, World Psychiatric Association World Psychiatric Association. (2008). Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research, 100(1-3), 20-38.
20. Tang, Y. L., Ma, P. X., Jiang, F., Chen, Q., Wang, C. Y., & Cai, Z. J., et al. (2008). Clozapine in China. Pharmacopsychiatry, 41, 1-9.
21. Uchida, N., Chong, M. Y., Tan, C. H., Nagai, H., Tanaka, M., Lee, M. S., et al. (2007). International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry and Clinical Neurosciences, 61, 522-528.
22. WHO (World Health Organization) (1992). The ICD Classification of Mental and Behavioral Disorder. Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization.
23. WHO (2002). Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC index with DDDs. Oslo: WHO.
24. WHO (2005). WHO Mental Health Atlas 2005. Geneva: World Health Organization.
25. Xiang, Y. T., Weng, Y. Z., Leung, C. M., Tang, W. K., Ungvari, G. S., & Gerevich, J. (2007). Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Progress in Neuropsychopharmacology and Biological Psychiatry, 31, 756-60.
26. Xiang, Y. T., Weng, Y. Z., Leung, C. M., Tang, W. K., & Sandor, U. G. (2007). Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia. Human Psychopharmacology, 22, 173-180.
27. Yoshimura, R., Inoue, M., Sasaki, H., Kuroki, H., & Shinfuku, N. (2005). Gaps in psychotropic prescription pattern between various areas in Japan. Seishin Iryo, 38, 17-25 21 (In Japanese).
28. Yoshimura, R., Okamoto, T., Nakamura, J., Tateno, M., Otsuka, K., Takahashi, H., et al. (2006). Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: Research on East Asia Psychotropic Prescription Pattern-Antipsychotics study. Psychiatry and Clinical Neurosciences, 60(6), 778-779.